DelveInsight’s “Prader-Willi Syndrome (PWS) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prader-Willi Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Prader-Willi Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Prader-Willi Syndrome (PWS): An Overview
According to the US National Library of Medicine, Prader-Willi syndrome is a complex genetic condition affecting many body parts. This condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development in infancy. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes (the most common form of diabetes). The disease occurs due to the loss of function of several genes in a particular region of chromosome number 15. Among these are genes that provide instructions for making molecules called small nucleolar RNAs (snoRNAs).
According to NORD, Prader-Will syndrome (PWS) is the first syndromic form of the neurodevelopmental disorder that was confirmed to be caused due to imprinting errors leading to a multisystem genetic disorder characterized during infancy by lethargy, diminished muscle tone (hypotonia), feeding difficulties, poor weight gain and growth hormone deficiency.
Prader-Willi Syndrome (PWS) Market Key Facts
As per the Foundation for PWS Research, the disease occurs in approximately 1 out of every 15,000 births. It affects males and females with equal frequency and affects all races and ethnicities.
The estimates place the incidence between 1/10,000–30,000 individuals in the general population. In contrast, as per “Adult Prader-Willi Syndrome: An Update on Management by Luk Ho-Ming,” the incidence is about 1/15,000–25,000 live births. Although most of them are diagnosed during childhood, with the improvement of medical care, it is not uncommon for adult physicians to encounter PWS patients.
According to DelveInsight’s estimation, the total prevalent cases of Prader-Willi syndrome (PWS) were found to be ~47,000 for the seven Major Markets in the year 2017.
The Prader-Willi Syndrome Association (PWSA) estimates that the prevalence of PWS is approximately 1/12–15,000 people in the US. Using the more conservative estimate, this translates into a target population of about 22,000 at present, which is relatively low.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Prader-Willi Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Prader-Willi Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Prader-Willi Syndrome (PWS) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Prader-Willi Syndrome Epidemiology, Segmented by –
Prevalent cases of Prader-Willi Syndrome in the 7MM (2019-2032)
Prader-Willi Syndrome associated clinical manifestation in 7MM (2019-2032)
Diagnosed cases of Prader-Willi Syndrome in the 7MM (2019-2032)
Prader-Willi Syndrome cases by mutation types in 7MM (2019-2032)
Prader-Willi Syndrome (PWS) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prader-Willi Syndrome market or expected to be launched during the study period. The analysis covers the Prader-Willi Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Prader-Willi Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Prader-Willi Syndrome Market Will Evolve and Grow by 2032 @
Prader-Willi Syndrome (PWS) Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for the treatment of Prader-Willi Syndrome. Soleno Therapeutics is leading the therapeutics market with its Prader-Willi Syndrome drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Prader-Willi Syndrome (PWS) Therapeutics Market Include:
LG Life Sciences
And Many Others
Prader-Willi Syndrome (PWS) Drugs Covered in the Report Include:
Diazoxide choline controlled release (DCCR): Soleno Therapeutics
Intranasal carbetocin (LV-101): Levo Therapeutics
LV-101: Levo Therapeutics
Pitolisant: Harmony Biosciences
Diazoxide Controlled Release [DCCR]: Soleno Therapeutics
GDD3898: Lipidio Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Prader-Willi Syndrome Competitive Intelligence Analysis
4. Prader-Willi Syndrome Market Overview at a Glance
5. Prader-Willi Syndrome Disease Background and Overview
6. Prader-Willi Syndrome Patient Journey
7. Prader-Willi Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Prader-Willi Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Prader-Willi Syndrome Unmet Needs
10. Key Endpoints of Prader-Willi Syndrome Treatment
11. Prader-Willi Syndrome Marketed Products
12. Prader-Willi Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Prader-Willi Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Prader-Willi Syndrome Market Outlook (In US, EU5, and Japan)
16. Prader-Willi Syndrome Access and Reimbursement Overview
17. KOL Views on the Prader-Willi Syndrome Market
18. Prader-Willi Syndrome Market Drivers
19. Prader-Willi Syndrome Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
The global Airway Stent Market is expected to grow at a CAGR of 7.73% during the forecast period from 2022 to 2027. The increase in demand for airway stents is primarily attributed to the increasing prevalence of lung cancer and respiratory diseases. Moreover, the high adoption of therapeutic treatments such as endoscopic therapy, bronchoscopy, and other treatments and the rising preference for minimally invasive surgeries will also propel the market growth during the forecast period from 2022-2027.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States